Trial Profile
A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 10 Mar 2023 Status changed from completed to discontinued.
- 01 Feb 2023 Interim Results published in the Hematological Oncology
- 12 Dec 2022 Status changed from active, no longer recruiting to completed.